These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 39144292)

  • 41. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Durvalumab: A Review in Extensive-Stage SCLC.
    Al-Salama ZT
    Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer.
    Hao YY; Qiao YP; Cheng JD
    Int J Gen Med; 2021; 14():10483-10493. PubMed ID: 35002304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.
    Wan C; Zhang Y; Liu P; Mei X; Cheng G; Pang J; Chen S; Xu J; Malhotra J; Qian H; Du Y
    J Thorac Dis; 2023 Oct; 15(10):5648-5657. PubMed ID: 37969256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
    Cho BC; Yoh K; Perets R; Nagrial A; Spigel DR; Gutierrez M; Kim DW; Kotasek D; Rasco D; Niu J; Satouchi M; Ahn MJ; Lee DH; Maurice-Dror C; Siddiqi S; Ren Y; Altura RA; Bar J
    Lung Cancer; 2021 Sep; 159():162-170. PubMed ID: 34371366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-programmed death ligand 1 immunotherapy in patients with limited-stage small cell lung cancer: a real-world exploratory study.
    Yao N; Qin Z; Ma J; Lu J; Sun K; Zhang Y; Qu W; Cui L; Yuan S; Jiang A; Li N; Tong S; Yao Y
    J Chemother; 2023 Sep; 35(5):448-454. PubMed ID: 36124811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
    Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
    Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
    Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
    Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
    Peng J; Zhang L; Wang L; Feng H; Yao D; Meng R; Liu X; Li X; Liu N; Tan B; Huang Z; Li S; Meng X
    Radiat Oncol; 2023 Jul; 18(1):111. PubMed ID: 37403111
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis.
    Ma J; Tian Y; Hao S; Zheng L; Hu W; Zhai X; Meng D; Zhu H
    J Neurooncol; 2022 Sep; 159(3):685-693. PubMed ID: 35976547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
    Xue L; Chen B; Lin J; Peng J
    Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study.
    Shen S; Li X; Guo S; Xu L; Yan N
    Front Oncol; 2024; 14():1391828. PubMed ID: 39040456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES-SCLC: A systematic review and network meta-analysis of RCTs and RWSs.
    Kang R; Ma J; Ai B; Liu J; Zheng Z; Yu J
    Thorac Cancer; 2024 Oct; ():. PubMed ID: 39397360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of immune checkpoint inhibitors plus platinum-etoposide
    Chen Y; Shang H; Yang Y; Wang Q; Gao X; Huang G
    Transl Cancer Res; 2024 Aug; 13(8):4146-4158. PubMed ID: 39262463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.